Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
Status:
Not yet recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
Ⅶ. Study procedures (summary)
1. Written informed consent must be obtained before any study specific procedures are
undertaken.
Qualified participants were identified at the pre-anesthesia evaluation clinic or ward.
The informed consents are obtained from the patient in the ward at night before the
operation.
2. The process of the experiment (brief describe) In the preoperative waiting area, the
patients are randomly assigned and divided into two groups according to the allocation
sequence table (corresponding to 1:1 randomization) generated by the computer. The
propofol group was both induced and maintained at an effect-site concentration (Ce) of
2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system. The sevoflurane group was
maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar
concentration of 0.7-1.3). During the operation, the dose of anesthetic drugs
(propofol/fentanyl /remifentanil and sevoflurane/cisatracurium/rocuronium) are adjusted
to maintain the mean arterial pressure and heartbeat fluctuations within 20% of the
baseline value and Entropy (or BIS) value at 40-60in both groups. The following patient
data were recorded, the type of anesthesia, sex, age at the time of surgery,
preoperative Karnofsky performance status (KPS) score and functional capacity, the
postoperative complications within 30 days (according Clavien-Dindo classification), ASA
physical status scores, tumor marker ,tumor size, intraoperative blood loss/transfusion,
duration of surgery, duration of anesthesia, total opioid (remifentanil/fentanyl) use,
postoperative radiation therapy, postoperative chemotherapy, postoperative concurrent
chemoradiotherapy, the presence of disease progression, and 6-month, 1-year, 3-year and
5-year overall survival and Karnofsky performance status score were recorded.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital